4.6 Review

Potential Therapies Targeting Metabolic Pathways in Cancer Stem Cells

Journal

CELLS
Volume 10, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/cells10071772

Keywords

cancer stem cell; fatty acid metabolism; glycolysis; glutamninolysis; metabolic pathway; metabolic plasticity; mitochondrial respiration

Categories

Funding

  1. Ministry of Science and Technology [MOST104-2314-B-715-003-MY3, MOST104-2627-M-715-002, MOST104-2320-B-715-006-MY2, MOST105-2627-M-715-001, MOST106-2627-M-371-001, MOST106-2320-B-371-002, MOST107-2320-B-371-002, MOST108-2320-B-371-001, MOST 109-2320-B-371-004]
  2. Changhua Christian Hospital [107-CCH-NPI-052, 108-CCH-MST-168]
  3. Taipei Medical University [108-5403-003-112]
  4. Ministry of Science and Technology, Taiwan [MOST 109-2314-B-038-021-MY3]

Ask authors/readers for more resources

Cancer stem cells (CSCs) play a crucial role in cancer treatment and progression, with unique metabolic characteristics that differ from normal cells. Studying the metabolic pathways that CSCs rely on can provide new opportunities and methods for cancer treatment.
Cancer stem cells (CSCs) are heterogeneous cells with stem cell-like properties that are responsible for therapeutic resistance, recurrence, and metastasis, and are the major cause for cancer treatment failure. Since CSCs have distinct metabolic characteristics that plays an important role in cancer development and progression, targeting metabolic pathways of CSCs appears to be a promising therapeutic approach for cancer treatment. Here we classify and discuss the unique metabolisms that CSCs rely on for energy production and survival, including mitochondrial respiration, glycolysis, glutaminolysis, and fatty acid metabolism. Because of metabolic plasticity, CSCs can switch between these metabolisms to acquire energy for tumor progression in different microenvironments compare to the rest of tumor bulk. Thus, we highlight the specific conditions and factors that promote or suppress CSCs properties to portray distinct metabolic phenotypes that attribute to CSCs in common cancers. Identification and characterization of the features in these metabolisms can offer new anticancer opportunities and improve the prognosis of cancer. However, the therapeutic window of metabolic inhibitors used alone or in combination may be rather narrow due to cytotoxicity to normal cells. In this review, we present current findings of potential targets in these four metabolic pathways for the development of more effective and alternative strategies to eradicate CSCs and treat cancer more effectively in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available